- Home
- ZION vs KRYS Comparison
ZION vs KRYS Comparison
Compare ZION & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZION | KRYS |
|---|---|---|
| Founded | 1873 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 10.3B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | ZION | KRYS |
|---|---|---|
| Price | $71.69 | $341.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 11 |
| Target Price | $65.33 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 1.6M | 333.5K |
| Earning Date | 04-20-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.88% | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | N/A | ★ 1.83 |
| Revenue | N/A | ★ $389,130,000.00 |
| Revenue This Year | $8.57 | $38.74 |
| Revenue Next Year | $4.67 | $32.53 |
| P/E Ratio | ★ $10.32 | $193.87 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $46.21 | $130.50 |
| 52 Week High | $73.34 | $382.54 |
Technical Indicators
Market Signals| Indicator | ZION | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 60.98 | 47.13 |
| Support Level | $58.17 | $246.17 |
| Resistance Level | N/A | $382.33 |
| Average True Range (ATR) | 1.52 | 16.76 |
| MACD | -0.01 | -5.22 |
| Stochastic Oscillator | 65.41 | 24.96 |
Price Performance
Historical ComparisonAbout ZION Zions Bancorporation N.A.
Zions Bancorp is a US regional bank with around $90 billion in total assets as of Sept. 30, 2025. Headquartered in Salt Lake City, Utah, Zions' branch network is in the Western and Southwestern United States and includes seven affiliate banks in these markets. The bank has a heavy focus on small and midsize commercial banking.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.